Pancragen vs Spermidine
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
PancragenAnti-Aging & LongevityCognitive Enhancement
Spermidine- Summary
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- Spermidine is a naturally occurring polyamine found in all living cells, with exceptionally high concentrations in wheat germ, aged cheese, and human sperm. It is the most studied autophagy-inducing dietary compound, shown to extend lifespan across multiple species and reduce cardiovascular and cognitive aging.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- ~30–60 minutes, but gut bacteria produce it continuously; supplementation raises tissue levels over weeks
- Admin Route
- SubQ, Oral
- Oral
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 1–5 mg
- Frequency
- Daily for 10–30 days
- Once daily
- Key Benefits
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- Induces autophagy — cellular self-cleaning
- Extends lifespan in yeast, flies, worms, and mice
- Reduces cardiovascular aging and arterial stiffness
- Reduces all-cause mortality (human epidemiological data)
- Neuroprotective: reduces amyloid and tau pathology
- Promotes hair growth (anagen phase activation)
- Reduces age-related immune decline
- Improves memory in aging models
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Generally very well tolerated
- Rare: mild GI discomfort at high doses
- May temporarily reduce some gut bacteria species
- Rare: headache at initiation
- Stacks With
- —
- —